City Therapeutics: director John Maraganore received 610,759 shares

What happened John Maraganore, director, converted derivative securities into 610,759 common shares on Oct 19, 2026 (price reported as N/A). The filing also shows disposals by conversion on Oct 19, 2026 of 500,000 shares and 56,095 shares at $0.00 (derivative). Separately, the filing reports a grant/award of 22,649 derivative shares on Oct 15, 2026 at $0.00 (total reported value $0).

Key details

• Transaction dates and prices:
  • Oct 19, 2026: conversion of derivative security — acquired 610,759 shares, price N/A.
  • Oct 19, 2026: conversion of derivative security — disposed 500,000 shares at $0.00 (derivative).
  • Oct 19, 2026: conversion of derivative security — disposed 56,095 shares at $0.00 (derivative).
  • Oct 15, 2026: grant/award (derivative) — acquired 22,649 shares at $0.00 (reported value $0).
• Shares owned after the transaction: not reported in the details provided.
• Footnotes from the filing:
  • F1: Each share of Series Seed and Series A convertible preferred stock was convertible into common stock on a one-to-1.0983 basis at the holder's option and automatically converted into common stock upon the closing of the issuer's initial public offering on Oct 19, 2026 without payment of consideration; the preferred stock had no expiration date.
  • F2: The shares underlying the Oct 15, 2026 option award vest in full upon the earlier of Oct 15, 2027 or the date of the issuer's next annual meeting of stockholders, subject to the reporting person's continued service.
• Filing and reporting dates: Form 4 filed Oct 19, 2026; period of report Oct 15, 2026. The provided details do not indicate that the filing was late.

Why it may matter

• The Oct 19, 2026 entries reflect conversions of preferred stock into common stock and reported disposals associated with those conversions. The Oct 15, 2026 entry is a derivative award that vests subject to continued service per the footnote. This filing does not show why the insider traded or why the company acted.